Pelvic Health Electrically Evoked Recording (PEER) 2 Study

NCT ID: NCT05200923

Last Updated: 2025-01-13

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 300 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-01-18
• Study Completion Date: 2026-12-18

Brief Summary

To collect physiological signals at several timepoints during the therapy evaluation period.

Detailed Description

This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this non-applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.)

Conditions

Overactive Bladder; Fecal Incontinence; Urinary Retention

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: DEVICE_FEASIBILITY
• Blinding Strategy: NONE

Study Groups

Pelvic health Electrically Evoked Recording (PEER) 2 Study

Collect physiological signals

Group Type: EXPERIMENTAL

Sacral Neuromodulation

Intervention Type: DEVICE

Sacral neuromodulation delivers electrical stimulation to a sacral nerve

Interventions

Sacral Neuromodulation

Sacral neuromodulation delivers electrical stimulation to a sacral nerve

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. 18 years of age or older

2. Candidate for or undergoing Medtronic InterStim lead implant for labeled indication* requiring an advanced evaluation

3. Willing and able to provide signed and dated informed consent

4. Willing and able to independently and accurately complete diaries, questionnaires, attend visits, and comply with the study protocol

5. Willing to maintain current regimen (dosage and frequency) of any OAB medication from baseline diary through the end of therapy evaluation

6. For subjects with urinary urge incontinence, have a diagnosis of OAB as demonstrated on a voiding diary by having a minimum of 3 episodes of urinary urge incontinence in the first 72 hours (Episodes must have a mild, moderate, or severe degree of urgency to meet this criterion) of the voiding diary.

7. For subjects with urinary frequency, have a diagnosis of OAB as demonstrated on a voiding diary with greater than or equal to 8 urgency frequency episodes per day within the first 72 hours of the voiding diary.

Note*: Candidate for or undergoing a Medtronic InterStim lead implant for labeled indication means that a clinical decision has already been made between a physician and the patient to undergo Medtronic Interstim lead implant to treat the subject's condition. This decision is to be made prior to discussing with the patient whether to enroll in the study.

1. 18 years of age or older

2. Candidate for or undergoing Medtronic InterStim lead implant for labeled indication* requiring an advanced evaluation

3. Willing and able to provide signed and dated informed consent

4. Willing and able to independently and accurately complete diaries, questionnaires, attend visits, and comply with the study protocol

5. Willing to maintain current regimen (dosage and frequency) of any NOUR medication from baseline diary through the end of therapy evaluation

6. Have a diagnosis of non-obstructive urinary retention as demonstrated by a urinary voiding diary with a minimum of 5 clean intermittent self-catheterizations in a 7-day period; and chronic non-obstructive urinary retention with an elevated postvoid residual (PVR) that has persisted for at least six months and is documented on two or more separate occasions.

Note*: Candidate for or undergoing a Medtronic InterStim lead implant for labeled indication means that a clinical decision has already been made between a physician and the patient to undergo Medtronic Interstim lead implant to treat the subject's condition. This decision is to be made prior to discussing with the patient whether to enroll in the study.

1. 18 years of age or older

2. Candidate for or undergoing Medtronic InterStim lead implant labeled indication* requiring an advanced evaluation

3. Willing and able to provide signed and dated informed consent

4. Willing and able to independently and accurately complete diaries, questionnaires, attend visits, and comply with the study protocol

5. Willing to maintain current regimen (dosage and frequency) of any FI medication from baseline diary through the end of therapy evaluation

6. Have a diagnosis of fecal incontinence as demonstrated by a bowel diary as greater than or equal to 2 incontinent episodes of more than staining (i.e., either slight, moderate, or severe soiling) per week

Note*: Candidate for or undergoing a Medtronic InterStim lead implant for labeled indication means that a clinical decision has already been made between a physician and the patient to undergo Medtronic Interstim lead implant to treat the subject's condition. This decision is to be made prior to discussing with the patient whether to enroll in the study.

Exclusion Criteria

1. Currently enrolled or planning to enroll in an interventional clinical study that could potentially confound the study results (co-enrollment in an interventional study is only allowed when documented pre-approval is obtained from the Medtronic study manager or designee)

2. Implanted with a neurostimulator, pacemaker or defibrillator

3. Pelvic floor muscle dysfunction due to surgical intervention or injury

4. Have neurological conditions such as multiple sclerosis, clinically significant peripheral neuropathy or spinal cord injury (e.g., paraplegia)

5. History of diabetes unless the diabetes is well-controlled through diet and/or medications

6. Have symptomatic urinary tract infection (UTI)

7. Have primary stress incontinence or mixed incontinence where the stress component overrides the urge component

8. Treatment of voiding behavior with botulinum toxin in the past 9 months or any plan to have botulinum toxin treatment during the study

9. Treatment of symptoms with tibial neuromodulation therapy in the last 3 months

10. Have knowledge of planned magnetic resonance imaging (MRIs) during the therapy evaluation portion of the study

11. Have knowledge of planned shortwave diathermy, microwave diathermy, or therapeutic diathermy

12. Women who are pregnant or planning to become pregnant

13. Current urinary tract mechanical obstruction (e.g. benign prostatic enlargement or urethral stricture)

14. Characteristics indicating a poor understanding of the study or characteristics that indicate the subject may have poor compliance with the study protocol requirements

1. Currently enrolled or planning to enroll in an interventional clinical study that could potentially confound the study results (co-enrollment in an interventional study is only allowed when documented pre-approval is obtained from the Medtronic study manager or designee)

2. Implanted with a neurostimulator, pacemaker or defibrillator

3. Pelvic floor muscle dysfunction due to surgical intervention or injury

4. Have neurological conditions such as multiple sclerosis, clinically significant peripheral neuropathy or spinal cord injury (e.g., paraplegia)

5. History of diabetes unless the diabetes is well-controlled through diet and/or medications

6. Have symptomatic urinary tract infection (UTI)

7. Treatment of symptoms with tibial neuromodulation therapy in the last 3 months

8. Have knowledge of planned magnetic resonance imaging (MRIs) during the therapy evaluation portion of the study

9. Have knowledge of planned shortwave diathermy, microwave diathermy, or therapeutic diathermy

10. Women who are pregnant or planning to become pregnant

11. Current urinary tract mechanical obstruction (e.g. benign prostatic enlargement or urethral stricture)

12. Characteristics indicating a poor understanding of the study or characteristics that indicate the subject may have poor compliance with the study protocol requirements

1. Currently enrolled or planning to enroll in an interventional clinical study that could potentially confound the study results (co-enrollment in an interventional study is only allowed when documented pre-approval is obtained from the Medtronic study manager or designee)

2. Implanted with a neurostimulator, pacemaker or defibrillator

3. Pelvic floor muscle dysfunction due to surgical intervention or injury

4. Have neurological conditions such as multiple sclerosis, clinically significant peripheral neuropathy or spinal cord injury (e.g., paraplegia)

5. Have uncorrected high grade internal rectal prolapse

6. Treatment of symptoms with tibial neuromodulation therapy in the last 3 months

7. Have knowledge of planned magnetic resonance imaging (MRIs) during the therapy evaluation portion of the study

8. Have knowledge of planned shortwave diathermy, microwave diathermy, or therapeutic diathermy

9. Women who are pregnant or planning to become pregnant

10. Characteristics indicating a poor understanding of the study or characteristics that indicate the subject may have poor compliance with the study protocol requirements

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

MedtronicNeuro

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Anne Miller

Role: STUDY_DIRECTOR

Medtronic Pelvic Health

Locations

Indiana University Health Methodist Research Institute

Indianapolis, Indiana, United States

Ochsner Clinic Foundation

New Orleans, Louisiana, United States

Mayo Clinic Urology/Urogynecology Department

Rochester, Minnesota, United States

University Hospitals Cleveland Medical Center

Cleveland, Ohio, United States

OhioHealth Physician's Group Urology

Hilliard, Ohio, United States

DHR Health Institute for Research and Development

Edinburg, Texas, United States

Countries

United States

Other Identifiers

MDT20063

Identifier Type: -

Identifier Source: org_study_id